CCR3 Polyclonal antibody
CCR3 Polyclonal Antibody for IHC, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human and More (1)
Applications
IHC, ELISA
Conjugate
Unconjugated
验证数据展示
经过测试的应用
Positive IHC detected in | human tonsillitis tissue, human lymphoma tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
推荐稀释比
Application | Dilution |
---|---|
Immunohistochemistry (IHC) | IHC : 1:100-1:400 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
发表文章中的应用
IHC | See 2 publications below |
产品信息
The immunogen of 22351-1-AP is CCR3 Fusion Protein expressed in E. coli.
Tested Applications | IHC, ELISA Application Description |
Cited Applications | IHC |
Tested Reactivity | human |
Cited Reactivity | human, mouse |
Immunogen | CCR3 fusion protein Ag17926 种属同源性预测 |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Full Name | chemokine (C-C motif) receptor 3 |
Synonyms | C C chemokine receptor type 3, C C CKR 3, CC CKR 3, CCR 3, CCR3, CD193, CKR3, CMKBR3, Eosinophil eotaxin receptor |
Calculated Molecular Weight | 355 aa, 41 kDa |
GenBank Accession Number | BC110297 |
Gene Symbol | CCR3 |
Gene ID (NCBI) | 1232 |
RRID | AB_2879085 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen Affinity purified |
UNIPROT ID | P51677 |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
实验方案
Product Specific Protocols | |
---|---|
IHC protocol for CCR3 antibody 22351-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
发表文章
Species | Application | Title |
---|---|---|
Int Immunopharmacol Emu oil alleviates atopic dermatitis-like responses by inhibiting Cdc42 signaling of keratinocyte | ||
Oncol Rep SYNPO2 promotes the development of BLCA by upregulating the infiltration of resting mast cells and increasing the resistance to immunotherapy |